secwatch.observer — SEC 8-K summary
======================================

Issuer:     CorMedix Inc. (CRMD)
CIK:        0001410098
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001213900-22-070820
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CorMedix reports Q3 net loss of $6.9M; provides DefenCath regulatory and NTAP updates
--------------------------------------------------------------------------------

- Net loss of $6.9M ($0.17 per share) improved from $8.6M loss ($0.22) in Q3 2021.
- Cash and short-term investments $59.0M; sufficient to fund operations through 2023.
- CMS increased NTAP reimbursement for DefenCath from $4,387.50 to $14,259.38 per visit.
- CMO implemented >95% of FDA corrective actions; NDA resubmission target end of Q1 2023.
- R&D expense decreased 51% to $2.3M; SG&A increased 21% to $4.6M on pre-launch activities.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/0001213900-22-070820-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1410098/000121390022070820/ea168353-8k_cormedix.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-070820

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer